Dysfunctional Immune System Reconstitution after Rituximab Exposure in Utero

Rebecca Clark*, Diana Lindsey, Susan Whiteway, Cecilia Mikita, Kenneth Lieuw

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Rituximab is an antibody that binds to B-lymphocytes and is increasingly used during pregnancy. As an immunoglobulin G, it will transfer across the placenta. Previous case reports describe a diversity of clinical presentations in neonates born following rituximab exposure in utero. Our case is the first to offer the long-term experience in the care of an infant with severe neutropenia and prolonged profound hypogammaglobulinemia and class-switching B cell defect after in utero rituximab exposure.

Original languageEnglish
Pages (from-to)E601-E604
JournalJournal of Pediatric Hematology/Oncology
Volume43
Issue number4
DOIs
StatePublished - May 2021

Keywords

  • hypogammaglobulinemia
  • in utero exposure
  • neutropenia
  • rituximab

Cite this